WO2009114040A3 - Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations - Google Patents

Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations Download PDF

Info

Publication number
WO2009114040A3
WO2009114040A3 PCT/US2008/077839 US2008077839W WO2009114040A3 WO 2009114040 A3 WO2009114040 A3 WO 2009114040A3 US 2008077839 W US2008077839 W US 2008077839W WO 2009114040 A3 WO2009114040 A3 WO 2009114040A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
methods
compositions
epitopes
antibodies
Prior art date
Application number
PCT/US2008/077839
Other languages
English (en)
Other versions
WO2009114040A2 (fr
Inventor
Paul Dal Monte
Jill Giles-Komar
George Heavner
David Knight
Mehrnaz Khossravi
Jeffrey Luo
David Shealy
David Volkin
Original Assignee
Centocor Ortho Biotech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc. filed Critical Centocor Ortho Biotech Inc.
Priority to EP08873207A priority Critical patent/EP2205276A4/fr
Publication of WO2009114040A2 publication Critical patent/WO2009114040A2/fr
Publication of WO2009114040A3 publication Critical patent/WO2009114040A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

L'invention concerne un anticorps anti-IL-12/23p40 qui se lie à une partie de la protéine IL-12 ou IL-23 correspondant à la sous-unité P40 de IL-12 ou IL-23, des compositions, formulations le contenant, et des procédés d'administration, qui ont des applications dans des utilisations et dispositifs de diagnostic et/ou thérapeutiques.
PCT/US2008/077839 2007-09-28 2008-09-26 Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations WO2009114040A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08873207A EP2205276A4 (fr) 2007-09-28 2008-09-26 Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97599707P 2007-09-28 2007-09-28
US60/975,997 2007-09-28

Publications (2)

Publication Number Publication Date
WO2009114040A2 WO2009114040A2 (fr) 2009-09-17
WO2009114040A3 true WO2009114040A3 (fr) 2010-05-27

Family

ID=40850818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/077839 WO2009114040A2 (fr) 2007-09-28 2008-09-26 Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations

Country Status (9)

Country Link
US (1) US20090181027A1 (fr)
EP (1) EP2205276A4 (fr)
CR (1) CR11399A (fr)
EC (1) ECSP10010056A (fr)
GT (1) GT201000073A (fr)
HN (1) HN2010000573A (fr)
NI (1) NI201000042A (fr)
SV (1) SV2010003517A (fr)
WO (1) WO2009114040A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103596978A (zh) * 2011-01-07 2014-02-19 阿布维公司 抗il-12/il-23抗体及其用途
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP3519049A4 (fr) * 2016-09-30 2020-05-27 Janssen Biotech, Inc. Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
JP7179717B2 (ja) * 2017-03-31 2022-11-29 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019106206A1 (fr) * 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Formulations liquides stables, à faible viscosité et à haute concentration en un anticorps anti-il-12/23p40
EP3793521A4 (fr) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
KR20230148273A (ko) * 2018-09-24 2023-10-24 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AU2020320910A1 (en) * 2019-07-30 2022-03-10 Akeso Biopharma, Inc. Anti-human p40 protein domain antibody and use thereof
EP4103606A4 (fr) * 2020-02-14 2024-04-10 Janssen Biotech Inc Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il-12/il23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214293A1 (en) * 2000-08-07 2005-09-29 Jill Giles-Komar ANTI-IL-12 antibodies and compositions
WO2006096488A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps en plateau

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
IL145134A0 (en) * 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
PT1314437E (pt) * 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
NZ583153A (en) * 2004-12-21 2011-06-30 Centocor Ortho Biotech Inc Anti-IL-12 antibodies, epitopes, compositions, methods and uses
WO2006138315A2 (fr) * 2005-06-15 2006-12-28 Schering Corporation Formulation d'anticorps stable
CA2613512A1 (fr) * 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
EP1977763A4 (fr) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Préparation stabilisatrice contenant des anticorps

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214293A1 (en) * 2000-08-07 2005-09-29 Jill Giles-Komar ANTI-IL-12 antibodies and compositions
WO2006096488A2 (fr) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps en plateau

Also Published As

Publication number Publication date
US20090181027A1 (en) 2009-07-16
SV2010003517A (es) 2010-08-10
NI201000042A (es) 2010-09-13
CR11399A (es) 2010-08-18
GT201000073A (es) 2012-04-19
WO2009114040A2 (fr) 2009-09-17
EP2205276A4 (fr) 2012-08-15
ECSP10010056A (es) 2010-04-30
EP2205276A2 (fr) 2010-07-14
HN2010000573A (es) 2012-12-10

Similar Documents

Publication Publication Date Title
WO2009114040A3 (fr) Anticorps anti-il-12/23p40, épitopes, formulations, compositions, procédés et utilisations
EA200870129A1 (ru) Человеческие антитела против il-23, композиции, способы и применение
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2008021076A3 (fr) Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins
WO2009140348A3 (fr) Anticorps anti-il-6/il-6r et procédés d'utilisation
WO2008118587A3 (fr) Applications thérapeutiques des cellules présentant un antigène humain par l'intermédiaire de la dectine.-1
EP2570137A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (DEC-205)
WO2007033230A3 (fr) Formulations d'anticorps anti-cd3
IL199216A (en) Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2008121615A3 (fr) Formulation d'anticorps
TN2011000229A1 (en) Antibody formulation
WO2007106744A8 (fr) Anticorps anti-5t4 et leurs utilisations
WO2011157741A3 (fr) Conjugués anticorps humain-médicament contre le facteur tissulaire
WO2012034039A3 (fr) Anticorps anti-il-1 bêta et leurs procédés d'utilisation
WO2009136286A3 (fr) Anticorps à réaction croisée anti-il-17a/il-17f et leurs procédés d'utilisation
EP2402373A3 (fr) Anticorps anti-EphB4 et procédés d'utilisation associés
NZ587765A (en) Methods for treating psoriasis
EP2371388A3 (fr) Formulations d'anticorps
EP3210625A3 (fr) Les peptides thérapeutiques comprenant la liaison aux anticorps polypeptide mhc de classe 1 série a (mica)
IL184152A (en) Monoclonal antibodies against nkg2a, preparations containing them, their use in drug preparation, methods of manufacture, and methods used in
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
IL214779A (en) Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation
WO2010128407A8 (fr) Anticorps anti-il-17f et leurs méthodes d'utilisation
WO2008130382A3 (fr) Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08873207

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010030486

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201011399

Country of ref document: CR

Ref document number: CR2010-011399

Country of ref document: CR

Ref document number: 2008873207

Country of ref document: EP